Resources
Comprehensive Tissue Genomic Profiling Reveals ALK-EML4 Fusionand TP53 Splice-Site Mutation in Metastatic Lung Adenocarcinoma
Clinical History & Chronological Summary Presentation: 31-year-old female with symptoms suggestive of right upper lobe lung involvement; PET-CT showed a RUL mass with lymphadenopathy and suspicious breast parenchymal uptake, raising
Liquid Biopsy Reveals ERBB3-PIK3CA Activation and MYC Amplification Driving Resistance in Metastatic Cervical Cancer
Clinical History & Chronological Summary Diagnosis: 50 y/ female diagnosed with poorly differentiated squamous cell carcinoma of cervix Initial Treatment: Initially treated with chemotherapy, brachytherapy, radiotherapy. Later, disease recurrence with
Directory of Services
Directory of Services of all diagnostic tests offered across our company’s portfolio.
1Cell ERA Newsletter | January 2026
The Jan 2026 edition of 1Cell.Ai Newsletter highlights key precision oncology trends including longitudinal liquid biopsy monitoring, clinical translation of single-cell technologies, and AI-driven decision support. It also features the
Comprehensive Liquid Biopsy Profiling Reveals Dual PIK3CA and ESR1 Mutations in Hormone Receptor-Positive Metastatic Breast Carcinoma
Patient: 73-year-old female with hormone receptor–positive, HER2-negative metastatic invasive ductal carcinoma of the breast (luminal B–like), with liver, bone, lung metastases and residual breast mass. Clinical Testing:Alterations: ESR1 (p.D538G) –
Metastatic Prostate Adenocarcinoma with TMPRSS2-ERG Fusion and MS-High Immunogenic Profile
Patient: 70-year-old male with metastatic prostate adenocarcinoma (T3bN3M1), Gleason score 9 (5+4), with seminal vesicle invasion, bladder wall infiltration, and necrotic pelvic lymph nodes. Clinical Testing:Alterations: TMPRSS2–ERG fusion (RNA, pathogenic)
1Cell ERA Newsletter | December 2025
This edition highlights key advances in precision oncology from SABCS 2025, focusing on breast cancer, emerging biomarkers, AI-driven risk stratification, and real-time monitoring through liquid biopsy. It also features TRINITY
Concurrent Tissue–Liquid–Normal Matched Multi-Omics Analysis Enables Precision Targeting in Advanced Lung Cancer
Patient: 49-year-old male, non-smoker, diagnosed with Stage IV lung adenocarcinoma with multiple bilateral pulmonary nodules and liver metastases. Clinical Testing:Alterations: MET exon 14 skipping (splice-site variant; ctDNA VAF 0.7%; RNA
Pediatric Glioblastoma with Comprehensive Genomic Profiling
Patient: 7-year-old male with glioblastoma multiforme (WHO Grade IV) post–partial resection and chemoradiotherapy Clinical Testing:Alterations: TP53, CDKN2A, LATS1, ATM, BRCA2, RAD50, MSH2, MLH1, PMS2, XPC, EGFR, NF1, PIK3CA, PTEN, NPRL2,
Multi-Omics Insights Driving Personalized Therapy in Metastatic Triple-Negative Breast Cancer (TNBC)
Patient: 55 years – Female with metastatic triple-negative breast carcinoma (ER–, PR–, HER2 1+) Clinical Testing:Alterations: TP53 (p.D281E), MSH3 (p.R454*), PIK3CA (p.E542K), SMAD4 (p.E307*), SMARCA4 (p.D1127H), NF2 (p.E335*), CD274 (PD-L1, RNA)Genes: TP53, MSH3,